These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Baumann P Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657 [TBL] [Abstract][Full Text] [Related]
6. The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study. Assimon MM; Pun PH; Al-Khatib SM; Brookhart MA; Gaynes BN; Winkelmayer WC; Flythe JE Nephrol Dial Transplant; 2022 Oct; 37(11):2241-2252. PubMed ID: 35793567 [TBL] [Abstract][Full Text] [Related]
7. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Edwards JG; Anderson I Drugs; 1999 Apr; 57(4):507-33. PubMed ID: 10235690 [TBL] [Abstract][Full Text] [Related]
8. Association of Antidepressant Medications With Incident Type 2 Diabetes Among Medicaid-Insured Youths. Burcu M; Zito JM; Safer DJ; Magder LS; dosReis S; Shaya FT; Rosenthal GL JAMA Pediatr; 2017 Dec; 171(12):1200-1207. PubMed ID: 29049533 [TBL] [Abstract][Full Text] [Related]
10. Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis. Assimon MM; Brookhart MA; Flythe JE J Am Soc Nephrol; 2019 Apr; 30(4):611-623. PubMed ID: 30885935 [TBL] [Abstract][Full Text] [Related]
11. Comparative safety of selective serotonin reuptake inhibitors among pediatric users with respect to adverse cardiac events. Czaja AS; Valuck RJ; Anderson HD Pharmacoepidemiol Drug Saf; 2013 Jun; 22(6):607-14. PubMed ID: 23456956 [TBL] [Abstract][Full Text] [Related]
12. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Preskorn SH Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Sánchez C; Hyttel J Cell Mol Neurobiol; 1999 Aug; 19(4):467-89. PubMed ID: 10379421 [TBL] [Abstract][Full Text] [Related]
15. Selective Serotonin Reuptake Inhibitors within Cells: Temporal Resolution in Cytoplasm, Endoplasmic Reticulum, and Membrane. Nichols AL; Blumenfeld Z; Luebbert L; Knox HJ; Muthusamy AK; Marvin JS; Kim CH; Grant SN; Walton DP; Cohen BN; Hammar R; Looger L; Artursson P; Dougherty DA; Lester HA J Neurosci; 2023 Mar; 43(13):2222-2241. PubMed ID: 36868853 [TBL] [Abstract][Full Text] [Related]
16. Association of Selective Serotonin Reuptake Inhibitors With the Risk of Type 2 Diabetes in Children and Adolescents. Sun JW; Hernández-Díaz S; Haneuse S; Bourgeois FT; Vine SM; Olfson M; Bateman BT; Huybrechts KF JAMA Psychiatry; 2021 Jan; 78(1):91-100. PubMed ID: 32876659 [TBL] [Abstract][Full Text] [Related]
20. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients. Shih YC; Bekele NB; Xu Y Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]